Steven & Alexandra Cohen Children's Medical Center, New York Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01425307
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Steven & Alexandra Cohen Foundation | Steven and Alexandra Cohen Children's Medical Center | Steven and Alexandra Cohen Foundation

Active Ingredients

Drugs in Phase 3 Trials (1)

hydroxyurea (hydrea) (1 trial)

Drugs in Phase 2 Trials (3)

3,4-Methyl​enedioxy​methamphetamine (2 trials)

nicotinamide (1 trial)

psilocybin (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Sickle Cell (Phase 3)

Hemoglobinopathies (Phase 2)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4